nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferoxamine—XDH—Doxorubicin—kidney cancer	0.472	1	CbGbCtD
Deferoxamine—Urethral disorder—Paclitaxel—kidney cancer	0.000548	0.00104	CcSEcCtD
Deferoxamine—Thrombocytopenia—Dactinomycin—kidney cancer	0.000548	0.00104	CcSEcCtD
Deferoxamine—Dyspnoea—Sorafenib—kidney cancer	0.000547	0.00104	CcSEcCtD
Deferoxamine—Cramps of lower extremities—Doxorubicin—kidney cancer	0.000541	0.00102	CcSEcCtD
Deferoxamine—Abdominal pain—Erlotinib—kidney cancer	0.00054	0.00102	CcSEcCtD
Deferoxamine—Body temperature increased—Erlotinib—kidney cancer	0.00054	0.00102	CcSEcCtD
Deferoxamine—Visual impairment—Paclitaxel—kidney cancer	0.000538	0.00102	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Sunitinib—kidney cancer	0.000538	0.00102	CcSEcCtD
Deferoxamine—Dysuria—Capecitabine—kidney cancer	0.000536	0.00101	CcSEcCtD
Deferoxamine—Nausea—Pazopanib—kidney cancer	0.000532	0.00101	CcSEcCtD
Deferoxamine—Paraesthesia—Sunitinib—kidney cancer	0.000531	0.001	CcSEcCtD
Deferoxamine—Convulsion—Vincristine—kidney cancer	0.000531	0.001	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Sorafenib—kidney cancer	0.00053	0.001	CcSEcCtD
Deferoxamine—Dyspnoea—Sunitinib—kidney cancer	0.000527	0.000997	CcSEcCtD
Deferoxamine—Pain—Sorafenib—kidney cancer	0.000525	0.000994	CcSEcCtD
Deferoxamine—Hypersensitivity—Vinblastine—kidney cancer	0.000523	0.000991	CcSEcCtD
Deferoxamine—Eye disorder—Paclitaxel—kidney cancer	0.000522	0.000989	CcSEcCtD
Deferoxamine—Myalgia—Vincristine—kidney cancer	0.000521	0.000987	CcSEcCtD
Deferoxamine—Hypersensitivity—Everolimus—kidney cancer	0.000521	0.000987	CcSEcCtD
Deferoxamine—Tinnitus—Paclitaxel—kidney cancer	0.000521	0.000986	CcSEcCtD
Deferoxamine—Leukopenia—Gemcitabine—kidney cancer	0.00052	0.000985	CcSEcCtD
Deferoxamine—Infestation NOS—Capecitabine—kidney cancer	0.000511	0.000967	CcSEcCtD
Deferoxamine—Infestation—Capecitabine—kidney cancer	0.000511	0.000967	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Sunitinib—kidney cancer	0.00051	0.000966	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Dactinomycin—kidney cancer	0.00051	0.000965	CcSEcCtD
Deferoxamine—Angiopathy—Paclitaxel—kidney cancer	0.000507	0.00096	CcSEcCtD
Deferoxamine—Pain—Sunitinib—kidney cancer	0.000505	0.000957	CcSEcCtD
Deferoxamine—Immune system disorder—Paclitaxel—kidney cancer	0.000505	0.000956	CcSEcCtD
Deferoxamine—Mediastinal disorder—Paclitaxel—kidney cancer	0.000504	0.000953	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Sorafenib—kidney cancer	0.000502	0.000951	CcSEcCtD
Deferoxamine—Renal failure—Capecitabine—kidney cancer	0.000502	0.000951	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Capecitabine—kidney cancer	0.000501	0.000948	CcSEcCtD
Deferoxamine—Pruritus—Everolimus—kidney cancer	0.0005	0.000948	CcSEcCtD
Deferoxamine—Anaphylactic shock—Vincristine—kidney cancer	0.0005	0.000946	CcSEcCtD
Deferoxamine—Oedema—Vincristine—kidney cancer	0.0005	0.000946	CcSEcCtD
Deferoxamine—Arrhythmia—Paclitaxel—kidney cancer	0.000499	0.000945	CcSEcCtD
Deferoxamine—Infection—Vincristine—kidney cancer	0.000496	0.00094	CcSEcCtD
Deferoxamine—Myalgia—Gemcitabine—kidney cancer	0.000495	0.000936	CcSEcCtD
Deferoxamine—Arthralgia—Gemcitabine—kidney cancer	0.000495	0.000936	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.000491	0.00093	CcSEcCtD
Deferoxamine—Nervous system disorder—Vincristine—kidney cancer	0.00049	0.000928	CcSEcCtD
Deferoxamine—Thrombocytopenia—Vincristine—kidney cancer	0.000489	0.000927	CcSEcCtD
Deferoxamine—Hepatic function abnormal—Doxorubicin—kidney cancer	0.000489	0.000926	CcSEcCtD
Deferoxamine—Urticaria—Sorafenib—kidney cancer	0.000488	0.000924	CcSEcCtD
Deferoxamine—Erythema—Paclitaxel—kidney cancer	0.000486	0.000921	CcSEcCtD
Deferoxamine—Diarrhoea—Vinblastine—kidney cancer	0.000486	0.00092	CcSEcCtD
Deferoxamine—Abdominal pain—Sorafenib—kidney cancer	0.000485	0.000919	CcSEcCtD
Deferoxamine—Body temperature increased—Sorafenib—kidney cancer	0.000485	0.000919	CcSEcCtD
Deferoxamine—Diarrhoea—Everolimus—kidney cancer	0.000484	0.000916	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Sunitinib—kidney cancer	0.000483	0.000915	CcSEcCtD
Deferoxamine—Pruritus—Erlotinib—kidney cancer	0.000483	0.000914	CcSEcCtD
Deferoxamine—Pain—Dactinomycin—kidney cancer	0.000478	0.000906	CcSEcCtD
Deferoxamine—Oedema—Gemcitabine—kidney cancer	0.000474	0.000898	CcSEcCtD
Deferoxamine—Anaphylactic shock—Gemcitabine—kidney cancer	0.000474	0.000898	CcSEcCtD
Deferoxamine—Infection—Gemcitabine—kidney cancer	0.000471	0.000892	CcSEcCtD
Deferoxamine—Dizziness—Vinblastine—kidney cancer	0.00047	0.000889	CcSEcCtD
Deferoxamine—Dizziness—Everolimus—kidney cancer	0.000468	0.000886	CcSEcCtD
Deferoxamine—Muscle spasms—Paclitaxel—kidney cancer	0.000468	0.000885	CcSEcCtD
Deferoxamine—Body temperature increased—Sunitinib—kidney cancer	0.000467	0.000884	CcSEcCtD
Deferoxamine—Abdominal pain—Sunitinib—kidney cancer	0.000467	0.000884	CcSEcCtD
Deferoxamine—Diarrhoea—Erlotinib—kidney cancer	0.000467	0.000884	CcSEcCtD
Deferoxamine—Hypotension—Vincristine—kidney cancer	0.000467	0.000884	CcSEcCtD
Deferoxamine—Bradycardia—Capecitabine—kidney cancer	0.000467	0.000884	CcSEcCtD
Deferoxamine—Nervous system disorder—Gemcitabine—kidney cancer	0.000465	0.00088	CcSEcCtD
Deferoxamine—Thrombocytopenia—Gemcitabine—kidney cancer	0.000464	0.000879	CcSEcCtD
Deferoxamine—Renal failure acute—Doxorubicin—kidney cancer	0.000463	0.000876	CcSEcCtD
Deferoxamine—Skin disorder—Gemcitabine—kidney cancer	0.00046	0.000872	CcSEcCtD
Deferoxamine—Vision blurred—Paclitaxel—kidney cancer	0.000458	0.000868	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000457	0.000866	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Vincristine—kidney cancer	0.000455	0.000862	CcSEcCtD
Deferoxamine—Urinary tract disorder—Capecitabine—kidney cancer	0.000453	0.000857	CcSEcCtD
Deferoxamine—Hypersensitivity—Sorafenib—kidney cancer	0.000452	0.000857	CcSEcCtD
Deferoxamine—Vomiting—Vinblastine—kidney cancer	0.000451	0.000855	CcSEcCtD
Deferoxamine—Dizziness—Erlotinib—kidney cancer	0.000451	0.000855	CcSEcCtD
Deferoxamine—Connective tissue disorder—Capecitabine—kidney cancer	0.000451	0.000853	CcSEcCtD
Deferoxamine—Vomiting—Everolimus—kidney cancer	0.00045	0.000852	CcSEcCtD
Deferoxamine—Urethral disorder—Capecitabine—kidney cancer	0.000449	0.000851	CcSEcCtD
Deferoxamine—Renal impairment—Doxorubicin—kidney cancer	0.000449	0.00085	CcSEcCtD
Deferoxamine—Paraesthesia—Vincristine—kidney cancer	0.000449	0.00085	CcSEcCtD
Deferoxamine—Headache—Vinblastine—kidney cancer	0.000445	0.000842	CcSEcCtD
Deferoxamine—Angioedema—Paclitaxel—kidney cancer	0.000444	0.000841	CcSEcCtD
Deferoxamine—Headache—Everolimus—kidney cancer	0.000443	0.000839	CcSEcCtD
Deferoxamine—Hypotension—Gemcitabine—kidney cancer	0.000443	0.000839	CcSEcCtD
Deferoxamine—Abdominal pain—Dactinomycin—kidney cancer	0.000442	0.000837	CcSEcCtD
Deferoxamine—Body temperature increased—Dactinomycin—kidney cancer	0.000442	0.000837	CcSEcCtD
Deferoxamine—Visual impairment—Capecitabine—kidney cancer	0.000442	0.000837	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Doxorubicin—kidney cancer	0.000441	0.000836	CcSEcCtD
Deferoxamine—Leukopenia—Paclitaxel—kidney cancer	0.000435	0.000824	CcSEcCtD
Deferoxamine—Hypersensitivity—Sunitinib—kidney cancer	0.000435	0.000824	CcSEcCtD
Deferoxamine—Pruritus—Sorafenib—kidney cancer	0.000434	0.000823	CcSEcCtD
Deferoxamine—Vomiting—Erlotinib—kidney cancer	0.000434	0.000822	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000432	0.000818	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Vincristine—kidney cancer	0.000431	0.000817	CcSEcCtD
Deferoxamine—Eye disorder—Capecitabine—kidney cancer	0.000428	0.000811	CcSEcCtD
Deferoxamine—Headache—Erlotinib—kidney cancer	0.000428	0.00081	CcSEcCtD
Deferoxamine—Tinnitus—Capecitabine—kidney cancer	0.000427	0.000809	CcSEcCtD
Deferoxamine—Pain—Vincristine—kidney cancer	0.000427	0.000809	CcSEcCtD
Deferoxamine—Paraesthesia—Gemcitabine—kidney cancer	0.000426	0.000806	CcSEcCtD
Deferoxamine—Dyspnoea—Gemcitabine—kidney cancer	0.000423	0.0008	CcSEcCtD
Deferoxamine—Nausea—Vinblastine—kidney cancer	0.000422	0.000799	CcSEcCtD
Deferoxamine—Convulsion—Paclitaxel—kidney cancer	0.000421	0.000798	CcSEcCtD
Deferoxamine—Nausea—Everolimus—kidney cancer	0.00042	0.000796	CcSEcCtD
Deferoxamine—Diarrhoea—Sorafenib—kidney cancer	0.00042	0.000796	CcSEcCtD
Deferoxamine—Pruritus—Sunitinib—kidney cancer	0.000418	0.000792	CcSEcCtD
Deferoxamine—Angiopathy—Capecitabine—kidney cancer	0.000416	0.000788	CcSEcCtD
Deferoxamine—Immune system disorder—Capecitabine—kidney cancer	0.000414	0.000784	CcSEcCtD
Deferoxamine—Myalgia—Paclitaxel—kidney cancer	0.000414	0.000784	CcSEcCtD
Deferoxamine—Arthralgia—Paclitaxel—kidney cancer	0.000414	0.000784	CcSEcCtD
Deferoxamine—Mediastinal disorder—Capecitabine—kidney cancer	0.000413	0.000782	CcSEcCtD
Deferoxamine—Hypersensitivity—Dactinomycin—kidney cancer	0.000412	0.00078	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000411	0.000779	CcSEcCtD
Deferoxamine—Arrhythmia—Capecitabine—kidney cancer	0.00041	0.000776	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000409	0.000775	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Vincristine—kidney cancer	0.000409	0.000774	CcSEcCtD
Deferoxamine—Dizziness—Sorafenib—kidney cancer	0.000406	0.000769	CcSEcCtD
Deferoxamine—Pain—Gemcitabine—kidney cancer	0.000405	0.000768	CcSEcCtD
Deferoxamine—Nausea—Erlotinib—kidney cancer	0.000405	0.000768	CcSEcCtD
Deferoxamine—Diarrhoea—Sunitinib—kidney cancer	0.000404	0.000765	CcSEcCtD
Deferoxamine—Blood creatinine increased—Doxorubicin—kidney cancer	0.0004	0.000758	CcSEcCtD
Deferoxamine—Erythema—Capecitabine—kidney cancer	0.000399	0.000756	CcSEcCtD
Deferoxamine—Oedema—Paclitaxel—kidney cancer	0.000397	0.000752	CcSEcCtD
Deferoxamine—Anaphylactic shock—Paclitaxel—kidney cancer	0.000397	0.000752	CcSEcCtD
Deferoxamine—Body temperature increased—Vincristine—kidney cancer	0.000395	0.000748	CcSEcCtD
Deferoxamine—Abdominal pain—Vincristine—kidney cancer	0.000395	0.000748	CcSEcCtD
Deferoxamine—Infection—Paclitaxel—kidney cancer	0.000394	0.000747	CcSEcCtD
Deferoxamine—Dizziness—Sunitinib—kidney cancer	0.000391	0.00074	CcSEcCtD
Deferoxamine—Shock—Paclitaxel—kidney cancer	0.000391	0.000739	CcSEcCtD
Deferoxamine—Vomiting—Sorafenib—kidney cancer	0.00039	0.000739	CcSEcCtD
Deferoxamine—Nervous system disorder—Paclitaxel—kidney cancer	0.000389	0.000737	CcSEcCtD
Deferoxamine—Thrombocytopenia—Paclitaxel—kidney cancer	0.000389	0.000736	CcSEcCtD
Deferoxamine—Tachycardia—Paclitaxel—kidney cancer	0.000387	0.000734	CcSEcCtD
Deferoxamine—Skin disorder—Paclitaxel—kidney cancer	0.000386	0.00073	CcSEcCtD
Deferoxamine—Headache—Sorafenib—kidney cancer	0.000385	0.000728	CcSEcCtD
Deferoxamine—Muscle spasms—Capecitabine—kidney cancer	0.000384	0.000727	CcSEcCtD
Deferoxamine—Diarrhoea—Dactinomycin—kidney cancer	0.000383	0.000725	CcSEcCtD
Deferoxamine—Vision blurred—Capecitabine—kidney cancer	0.000376	0.000712	CcSEcCtD
Deferoxamine—Vomiting—Sunitinib—kidney cancer	0.000376	0.000711	CcSEcCtD
Deferoxamine—Body temperature increased—Gemcitabine—kidney cancer	0.000375	0.00071	CcSEcCtD
Deferoxamine—Hypotension—Paclitaxel—kidney cancer	0.000371	0.000702	CcSEcCtD
Deferoxamine—Headache—Sunitinib—kidney cancer	0.00037	0.000701	CcSEcCtD
Deferoxamine—Asthma—Doxorubicin—kidney cancer	0.000369	0.000699	CcSEcCtD
Deferoxamine—Hypersensitivity—Vincristine—kidney cancer	0.000368	0.000697	CcSEcCtD
Deferoxamine—Eosinophilia—Doxorubicin—kidney cancer	0.000366	0.000692	CcSEcCtD
Deferoxamine—Nausea—Sorafenib—kidney cancer	0.000365	0.000691	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000362	0.000685	CcSEcCtD
Deferoxamine—Leukopenia—Capecitabine—kidney cancer	0.000357	0.000676	CcSEcCtD
Deferoxamine—Paraesthesia—Paclitaxel—kidney cancer	0.000356	0.000675	CcSEcCtD
Deferoxamine—Vomiting—Dactinomycin—kidney cancer	0.000356	0.000673	CcSEcCtD
Deferoxamine—Dyspnoea—Paclitaxel—kidney cancer	0.000354	0.00067	CcSEcCtD
Deferoxamine—Nausea—Sunitinib—kidney cancer	0.000351	0.000665	CcSEcCtD
Deferoxamine—Dysuria—Doxorubicin—kidney cancer	0.000345	0.000654	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000343	0.000649	CcSEcCtD
Deferoxamine—Diarrhoea—Vincristine—kidney cancer	0.000342	0.000647	CcSEcCtD
Deferoxamine—Arthralgia—Capecitabine—kidney cancer	0.00034	0.000643	CcSEcCtD
Deferoxamine—Myalgia—Capecitabine—kidney cancer	0.00034	0.000643	CcSEcCtD
Deferoxamine—Pain—Paclitaxel—kidney cancer	0.000339	0.000643	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000337	0.000639	CcSEcCtD
Deferoxamine—Pruritus—Gemcitabine—kidney cancer	0.000335	0.000635	CcSEcCtD
Deferoxamine—Nausea—Dactinomycin—kidney cancer	0.000332	0.000629	CcSEcCtD
Deferoxamine—Dizziness—Vincristine—kidney cancer	0.00033	0.000626	CcSEcCtD
Deferoxamine—Infestation NOS—Doxorubicin—kidney cancer	0.000329	0.000623	CcSEcCtD
Deferoxamine—Infestation—Doxorubicin—kidney cancer	0.000329	0.000623	CcSEcCtD
Deferoxamine—Oedema—Capecitabine—kidney cancer	0.000326	0.000617	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000325	0.000615	CcSEcCtD
Deferoxamine—Diarrhoea—Gemcitabine—kidney cancer	0.000324	0.000614	CcSEcCtD
Deferoxamine—Renal failure—Doxorubicin—kidney cancer	0.000324	0.000613	CcSEcCtD
Deferoxamine—Infection—Capecitabine—kidney cancer	0.000324	0.000613	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Doxorubicin—kidney cancer	0.000323	0.000611	CcSEcCtD
Deferoxamine—Shock—Capecitabine—kidney cancer	0.00032	0.000607	CcSEcCtD
Deferoxamine—Nervous system disorder—Capecitabine—kidney cancer	0.000319	0.000605	CcSEcCtD
Deferoxamine—Thrombocytopenia—Capecitabine—kidney cancer	0.000319	0.000604	CcSEcCtD
Deferoxamine—Tachycardia—Capecitabine—kidney cancer	0.000318	0.000602	CcSEcCtD
Deferoxamine—Vomiting—Vincristine—kidney cancer	0.000318	0.000602	CcSEcCtD
Deferoxamine—Skin disorder—Capecitabine—kidney cancer	0.000316	0.000599	CcSEcCtD
Deferoxamine—Urticaria—Paclitaxel—kidney cancer	0.000315	0.000597	CcSEcCtD
Deferoxamine—Abdominal pain—Paclitaxel—kidney cancer	0.000314	0.000594	CcSEcCtD
Deferoxamine—Body temperature increased—Paclitaxel—kidney cancer	0.000314	0.000594	CcSEcCtD
Deferoxamine—Headache—Vincristine—kidney cancer	0.000313	0.000593	CcSEcCtD
Deferoxamine—Hypotension—Capecitabine—kidney cancer	0.000304	0.000576	CcSEcCtD
Deferoxamine—Vomiting—Gemcitabine—kidney cancer	0.000301	0.000571	CcSEcCtD
Deferoxamine—Bradycardia—Doxorubicin—kidney cancer	0.000301	0.00057	CcSEcCtD
Deferoxamine—Headache—Gemcitabine—kidney cancer	0.000297	0.000562	CcSEcCtD
Deferoxamine—Nausea—Vincristine—kidney cancer	0.000297	0.000562	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000297	0.000562	CcSEcCtD
Deferoxamine—Paraesthesia—Capecitabine—kidney cancer	0.000292	0.000554	CcSEcCtD
Deferoxamine—Hypersensitivity—Paclitaxel—kidney cancer	0.000292	0.000554	CcSEcCtD
Deferoxamine—Urinary tract disorder—Doxorubicin—kidney cancer	0.000292	0.000553	CcSEcCtD
Deferoxamine—Connective tissue disorder—Doxorubicin—kidney cancer	0.00029	0.00055	CcSEcCtD
Deferoxamine—Dyspnoea—Capecitabine—kidney cancer	0.00029	0.00055	CcSEcCtD
Deferoxamine—Urethral disorder—Doxorubicin—kidney cancer	0.00029	0.000549	CcSEcCtD
Deferoxamine—Visual impairment—Doxorubicin—kidney cancer	0.000285	0.000539	CcSEcCtD
Deferoxamine—Nausea—Gemcitabine—kidney cancer	0.000282	0.000533	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000281	0.000532	CcSEcCtD
Deferoxamine—Pruritus—Paclitaxel—kidney cancer	0.000281	0.000532	CcSEcCtD
Deferoxamine—Pain—Capecitabine—kidney cancer	0.000279	0.000527	CcSEcCtD
Deferoxamine—Eye disorder—Doxorubicin—kidney cancer	0.000276	0.000523	CcSEcCtD
Deferoxamine—Tinnitus—Doxorubicin—kidney cancer	0.000276	0.000522	CcSEcCtD
Deferoxamine—Diarrhoea—Paclitaxel—kidney cancer	0.000272	0.000514	CcSEcCtD
Deferoxamine—Angiopathy—Doxorubicin—kidney cancer	0.000268	0.000508	CcSEcCtD
Deferoxamine—Immune system disorder—Doxorubicin—kidney cancer	0.000267	0.000505	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Capecitabine—kidney cancer	0.000266	0.000504	CcSEcCtD
Deferoxamine—Mediastinal disorder—Doxorubicin—kidney cancer	0.000266	0.000504	CcSEcCtD
Deferoxamine—Arrhythmia—Doxorubicin—kidney cancer	0.000264	0.0005	CcSEcCtD
Deferoxamine—Dizziness—Paclitaxel—kidney cancer	0.000262	0.000497	CcSEcCtD
Deferoxamine—Urticaria—Capecitabine—kidney cancer	0.000259	0.00049	CcSEcCtD
Deferoxamine—Abdominal pain—Capecitabine—kidney cancer	0.000257	0.000488	CcSEcCtD
Deferoxamine—Body temperature increased—Capecitabine—kidney cancer	0.000257	0.000488	CcSEcCtD
Deferoxamine—Erythema—Doxorubicin—kidney cancer	0.000257	0.000487	CcSEcCtD
Deferoxamine—Vomiting—Paclitaxel—kidney cancer	0.000252	0.000478	CcSEcCtD
Deferoxamine—Headache—Paclitaxel—kidney cancer	0.000249	0.000471	CcSEcCtD
Deferoxamine—Muscle spasms—Doxorubicin—kidney cancer	0.000247	0.000468	CcSEcCtD
Deferoxamine—Vision blurred—Doxorubicin—kidney cancer	0.000242	0.000459	CcSEcCtD
Deferoxamine—Hypersensitivity—Capecitabine—kidney cancer	0.00024	0.000454	CcSEcCtD
Deferoxamine—Nausea—Paclitaxel—kidney cancer	0.000236	0.000446	CcSEcCtD
Deferoxamine—Pruritus—Capecitabine—kidney cancer	0.00023	0.000436	CcSEcCtD
Deferoxamine—Leukopenia—Doxorubicin—kidney cancer	0.00023	0.000436	CcSEcCtD
Deferoxamine—Convulsion—Doxorubicin—kidney cancer	0.000223	0.000422	CcSEcCtD
Deferoxamine—Diarrhoea—Capecitabine—kidney cancer	0.000223	0.000422	CcSEcCtD
Deferoxamine—Arthralgia—Doxorubicin—kidney cancer	0.000219	0.000415	CcSEcCtD
Deferoxamine—Myalgia—Doxorubicin—kidney cancer	0.000219	0.000415	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000218	0.000412	CcSEcCtD
Deferoxamine—Dizziness—Capecitabine—kidney cancer	0.000215	0.000408	CcSEcCtD
Deferoxamine—Anaphylactic shock—Doxorubicin—kidney cancer	0.00021	0.000398	CcSEcCtD
Deferoxamine—Oedema—Doxorubicin—kidney cancer	0.00021	0.000398	CcSEcCtD
Deferoxamine—Infection—Doxorubicin—kidney cancer	0.000209	0.000395	CcSEcCtD
Deferoxamine—Vomiting—Capecitabine—kidney cancer	0.000207	0.000392	CcSEcCtD
Deferoxamine—Shock—Doxorubicin—kidney cancer	0.000207	0.000391	CcSEcCtD
Deferoxamine—Nervous system disorder—Doxorubicin—kidney cancer	0.000206	0.00039	CcSEcCtD
Deferoxamine—Thrombocytopenia—Doxorubicin—kidney cancer	0.000206	0.000389	CcSEcCtD
Deferoxamine—Tachycardia—Doxorubicin—kidney cancer	0.000205	0.000388	CcSEcCtD
Deferoxamine—Headache—Capecitabine—kidney cancer	0.000204	0.000386	CcSEcCtD
Deferoxamine—Skin disorder—Doxorubicin—kidney cancer	0.000204	0.000386	CcSEcCtD
Deferoxamine—Hypotension—Doxorubicin—kidney cancer	0.000196	0.000372	CcSEcCtD
Deferoxamine—Nausea—Capecitabine—kidney cancer	0.000193	0.000366	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.000191	0.000362	CcSEcCtD
Deferoxamine—Paraesthesia—Doxorubicin—kidney cancer	0.000189	0.000357	CcSEcCtD
Deferoxamine—Dyspnoea—Doxorubicin—kidney cancer	0.000187	0.000354	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000181	0.000343	CcSEcCtD
Deferoxamine—Pain—Doxorubicin—kidney cancer	0.00018	0.00034	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000172	0.000325	CcSEcCtD
Deferoxamine—Urticaria—Doxorubicin—kidney cancer	0.000167	0.000316	CcSEcCtD
Deferoxamine—Body temperature increased—Doxorubicin—kidney cancer	0.000166	0.000314	CcSEcCtD
Deferoxamine—Abdominal pain—Doxorubicin—kidney cancer	0.000166	0.000314	CcSEcCtD
Deferoxamine—Hypersensitivity—Doxorubicin—kidney cancer	0.000155	0.000293	CcSEcCtD
Deferoxamine—Pruritus—Doxorubicin—kidney cancer	0.000149	0.000281	CcSEcCtD
Deferoxamine—Diarrhoea—Doxorubicin—kidney cancer	0.000144	0.000272	CcSEcCtD
Deferoxamine—Dizziness—Doxorubicin—kidney cancer	0.000139	0.000263	CcSEcCtD
Deferoxamine—Vomiting—Doxorubicin—kidney cancer	0.000133	0.000253	CcSEcCtD
Deferoxamine—Headache—Doxorubicin—kidney cancer	0.000132	0.000249	CcSEcCtD
Deferoxamine—Nausea—Doxorubicin—kidney cancer	0.000125	0.000236	CcSEcCtD
